{"id":28038,"date":"2021-09-25T09:00:23","date_gmt":"2021-09-25T07:00:23","guid":{"rendered":"https:\/\/semmelweis.hu\/english\/?p=28038"},"modified":"2021-09-24T09:33:51","modified_gmt":"2021-09-24T07:33:51","slug":"researchers-salon-molecular-oncology-and-personalized-therapy-in-focus","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/english\/2021\/09\/researchers-salon-molecular-oncology-and-personalized-therapy-in-focus\/","title":{"rendered":"Researchers\u2019 Salon: Molecular oncology and personalized therapy in focus"},"content":{"rendered":"
The first event of this year\u2019s Researchers\u2019 Salon featured presentations about diagnostics in molecular oncology and personalized therapy. The event was opened by dr. P\u00e9ter Ferdin\u00e1ndy, vice Rector for Science and Innovations of Semmelweis University.<\/div>\n

\"\"Due to the COVID-19 pandemic, the event series had to be cancelled last year. We thought that this event requires personal presence \u2013 added dr. P\u00e9ter Ferdin\u00e1ndy in his opening speech. He also added that they had to make some additional changes to the original plan so that spectators could follow this year\u2019s presentations online as well.<\/p>\n

Dr. J\u00f3zsef T\u00edm\u00e1r (university professor of the 2nd Department of Pathology) held a presentation entitled \u201cThe treatment options for tumors carrying mutant RAS genes: Is it impossible to effectively target RAS mutation?\u201c.<\/p>\n

\"\"\u201cPeople always say that treating RAS-mutated cancer remains the last oncological problem yet to be solved in the 21st century. RAS is a genetic disorder present in most human cancer types. RAS occur in some 20% to 30% of human tumors and was detected in 80-90% of specific cancer types, like pancreatic cancer.\u201d Dr. T\u00edm\u00e1r also added: for decades it was thought that these can\u2019t be handled, research results of the last few years seemed to advance significantly in this field providing solutions which were impossible before.\u00a0 \u201cCancer Moonshot\u201d is the name of a major program that has been launched in America. As a result of this project, a licensed medicine is now available which has been developed to fight mutant protein in lung cancer \u2013 this may unleash an avalanche of medical innovation. Our consortium would like to reach similar goals in Hungary: our aim is to develop a drug targeting the previously mentioned oncogenes. Furthermore, we want to develop new treatment alternatives which can be used in the treatment of these tumors and making medicines soon to be licensed more effective \u2013 summarized dr. J\u00f3zsef T\u00edm\u00e1r.<\/span><\/p>\n

\"\"Dr. Bal\u00e1zs Gy\u0151rffy (professor of the Department of Bioinformatics, physician of MTA) gave a speech entitled \u201dUtilizing omics data to identify prognostic and predictive oncological biomarkers\u201d. He introduced three bioinformatics devices which have been developed at the department and can solve oncological problems. The first device is able to detect the difference between normal gene expression and that of a cancer. The second one aims to find a correlation with the therapeutic response. The last device can identify the correlation between gene mutation and gene expression within a tumor. Dr. Bal\u00e1zs Gy\u0151rffy emphasized that different sources of data were used during the development process of these devices.\u00a0 \u201cWe included the omics data of more than a hundred thousand patients in the database, containing data related to gene expression, mutation and protein expression\u201d.<\/p>\n

\"\"The following presentation was held by dr. Csaba B\u00f6d\u00f6r (senior research fellow at the 1st Department of Pathology and Experimental Cancer Research) about \u201cGenomic techniques enhancing personalized therapy in oncohematology\u201d. He introduced molecular genomic methods and innovations (new generation sequencing, digital PCR based techniques) which have been integrated at Semmelweis University during the last three years. Dr. B\u00f6d\u00f6r stressed the importance of these techniques, as these can identify genetic differences in tumors. These differences can help in providing diagnosis and help clinicians choosing the optimal therapy. The purpose of the innovation is to enable a state-of-the-art diagnosis of cancer patients and to find a targeted treatment method. \u201cPrecision medicine has triggered high expectations. Clinicians also have a major role in this whole process and patients need to be informed in a correct way.\u201d \u2013 added dr. B\u00f6d\u00f6r. He emphasized that if patients regularly consult with a clinician, they can achieve good results with this method.<\/p>\n

\"\"Dr. Istv\u00e1n Pet\u00e1k (senior research fellow of the Department of Pharmacology and Phamacotherapy, molecular pharmacologist of Oncompass) held a presentation entitled \u201cTherapeutic decision support in the clinical use of precision oncology\u201d. \u201cBy the year 2020, humanity have accumulated knowledge about the genes that can cause cancer. In 95% of the cases healthcare professionals can identify the gene disorder responsible for causing tumor\u201d. He added: we have molecular diagnostics methods to examine how the tumor reacts to a specific drug, making it easier to choose from more than hundred types of medicine available. Artificial intelligence-powered medical technologies are rapidly evolving into applicable solutions for clinical practice, enabling us to provide the best, most effective personalized treatment for every patient.\u201d \u2013 pointed out dr. Istv\u00e1n Pet\u00e1k. Dr. Pet\u00e1k\u2019s presentation introduced the development of molecular diagnostics and artificial intelligence enabled medical devices that have been recognized several times during innovation competitions.<\/p>\n

 <\/p>\n

D\u00f3ra Horv\u00e1th, \u00c1d\u00e1m Szab\u00f3<\/p>\n

Photo: G\u00e1bor Ancsin<\/p>\n

Translation: Norbert Luk\u00e1cs<\/p>\n","protected":false},"excerpt":{"rendered":"

The first event of this year\u2019s Researchers\u2019 Salon featured presentations about diagnostics in molecular oncology and personalized therapy. The event was opened by dr. P\u00e9ter Ferdin\u00e1ndy, vice Rector for Science and Innovations of Semmelweis University. Due to the COVID-19 pandemic, the event series had to be cancelled last year. We thought that this event requires …<\/p>\n","protected":false},"author":101920,"featured_media":28039,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,17],"tags":[],"class_list":["post-28038","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-semmelweis-world"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/posts\/28038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/users\/101920"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/comments?post=28038"}],"version-history":[{"count":2,"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/posts\/28038\/revisions"}],"predecessor-version":[{"id":28046,"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/posts\/28038\/revisions\/28046"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/media\/28039"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/media?parent=28038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/categories?post=28038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/english\/wp-json\/wp\/v2\/tags?post=28038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}